Rates of Minor Adverse Events and Health Resource Utilization Postcolonoscopy

Rates of Minor Adverse Events and Health Resource Utilization Postcolonoscopy

BACKGROUND: Little is known about minor adverse events (MAEs) following outpatient colonoscopies and associated health care resource utilization.

Saved in:

Bibliographic Details
Main Authors:	Vladimir Marquez Azalgara, Maida J Sewitch, Lawrence Joseph, Alan N Barkun
Format:	Article
Language:	English
Published:	Wiley 2014-01-01
Series:	Canadian Journal of Gastroenterology and Hepatology
Online Access:	http://dx.doi.org/10.1155/2014/750587
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Different Screening Definitions have Little Impact on Polypectomy Rate Estimates
by: Mengzhu Jiang, et al.
Published: (2012-01-01)

Adenoma Detection Rates Decline with Increasing Procedural Hours in an Endoscopist’s Workload
by: Majid A Almadi, et al.
Published: (2015-01-01)

Pilot Validation Study: Canadian Global Rating Scale for Colonoscopy Services
by: Stéphanie Carpentier, et al.
Published: (2016-01-01)

Scanning and vicarious learning from adverse events in health care
Published: (2001-01-01)

Adverse Events of Antiepileptic Drugs Using Indonesian Version of Liverpool Adverse Events Profile
by: Astri Budikayanti, et al.
Published: (2018-01-01)

Analysis of postmarketing neuropsychiatric adverse events of avapritinib based on the FDA adverse event reporting system
by: Wei Mao, et al.
Published: (2025-01-01)

Musculoskeletal Adverse Events Associated with PCSK9 Inhibitors: Disproportionality Analysis of the FDA Adverse Event Reporting System
by: Lingqing Ding, et al.
Published: (2022-01-01)

Optimal Control of Renewable Resources Based on the Effective Utilization Rate
by: Rui Wu, et al.
Published: (2015-01-01)

Disproportionality analysis of upadacitinib-related adverse events in inflammatory bowel disease using the FDA adverse event reporting system
by: Shiyi Wang, et al.
Published: (2025-02-01)

Adverse events in different administration routes of amiodarone: a pharmacovigilance study based on the FDA adverse event reporting system
by: Jingrong Yang, et al.
Published: (2025-01-01)

Patient-Identified Quality Indicators for Colonoscopy Services
by: Maida J Sewitch, et al.
Published: (2013-01-01)

A disproportionality analysis of FDA adverse event reporting system events for misoprostol
by: Li Yang, et al.
Published: (2025-01-01)

Economic impact of potentially inappropriate prescribing and related adverse events in older people: a cost-utility analysis using Markov models
by: Kathleen Bennett, et al.
Published: (2019-01-01)

Neuropsychiatric adverse events associated with Glucagon-like peptide-1 receptor agonists: a pharmacovigilance analysis of the FDA Adverse Event Reporting System database
by: Wenchao Lu, et al.
Published: (2025-01-01)

A post-marketing pharmacovigilance study of triazole antifungals: adverse event data mining and analysis based on the FDA adverse event reporting system database
by: Yalan Tian, et al.
Published: (2025-01-01)

Evaluation of a mentorship matchmaking event at an academic research institution to reinforce the scientific workforce pathway for underrepresented minority groups
by: Sirena Gutierrez, et al.
Published: (2025-01-01)

Aseptic Meningitis as an Immune-Related Adverse Event after Pembrolizumab
by: Gian Lima, et al.
Published: (2019-01-01)

Examining vaccination-related adverse events in frequent neurodegenerative diseases
by: Shabnam Sodagari, et al.
Published: (2025-02-01)

Autoimmune pancerebellitis as an immune-related adverse event: an illustrative case
by: D. Valančius, et al.
Published: (2021-12-01)

Renal impairment and in-hospital adverse renal events in critically ill patients assessed by age-adapted estimated glomerular filtration rate criteria
by: Chong Zhang, et al.
Published: (2025-12-01)

Investigation of the total anticholinergic load of reported anticholinergic drug-related adverse events using the Japanese adverse drug event report database: a retrospective pharmacovigilance study
by: Yusuke Kan, et al.
Published: (2025-01-01)

Adverse events associated with the delivery of telerehabilitation: A scoping review protocol.
by: Thomas Yau, et al.
Published: (2024-01-01)

Diagnosis and Treatment of Rheumatic Adverse Events Related to Immune Checkpoint Inhibitors
by: Yan Xiao, et al.
Published: (2020-01-01)

Analysis of Adverse Events during Intrahospital Transportation of Critically Ill Patients
by: Francielli Mary Pereira Gimenez, et al.
Published: (2017-01-01)

Mania as a Rare Adverse Event Secondary to Steroid Eye Drops
by: Moayyad Alsalem, et al.
Published: (2022-01-01)

The Utility of Point of Care Test for Soluble ST2 in Predicting Adverse Cardiac Events during Acute Care of ST-Segment Elevation Myocardial Infarction
by: Anggoro Budi Hartopo, et al.
Published: (2018-01-01)

Utility of Serology in Determining Helicobacter pylori Eradication after Therapy
by: Carlo A Fallone, et al.
Published: (1998-01-01)

Adverse events in the nervous system associated with blinatumomab: a real-world study
by: Wen Gao, et al.
Published: (2025-02-01)

Association of high γ′ fibrinogen levels with adverse events in patients with COVID-19
by: Queen Revollido, et al.
Published: (2025-02-01)

Acknowledging and addressing real-world challenges to treating immune-related adverse events
by: Bonnie L Bermas, et al.
Published: (2024-07-01)

Factors Predicting Adverse Events Associated with Pregabalin Administered for Neuropathic Pain Relief
by: Yuko Kanbayashi, et al.
Published: (2014-01-01)

Impact of discontinuation of cephazolin prophylaxis on the incidence of postoperative adverse events in cataract surgery
by: Kazutaka Uchida, et al.
Published: (2025-01-01)

Clinical characteristics and potential biomarkers of thyroid and pituitary immune-related adverse events
by: Tomoko Kobayashi, et al.
Published: (2024-01-01)

Automatic tool for the reconciliation of serious adverse events for pharmacovigilance: design and implementation of Reconciliaid
by: Sara Contu, et al.
Published: (2025-01-01)

Comparisons of adverse events associated with immune checkpoint inhibitors in the treatment of non-small cell lung cancer: a real-world disproportionality analysis based on the FDA adverse event reporting system
by: Ruichen Gao, et al.
Published: (2025-02-01)

Comparing Patient and Endoscopist Perceptions of the Colonoscopy Indication
by: Maida J Sewitch, et al.
Published: (2010-01-01)

Adverse childhood experiences screening in pediatric primary care and changes in the rate of visits to social work and behavioral health
by: Sonya Negriff, et al.
Published: (2025-02-01)

Expanding on Abraxane Safety: Temporal Insights and Future Directions for Adverse Event Analysis [Letter]
by: Yang F, et al.
Published: (2025-02-01)

Analysis of ADR reports of cetuximab based on the FDA adverse event reporting system database
by: Shuai Zhao, et al.
Published: (2025-02-01)

A systematic review and meta-analysis assessing adverse event profile and tolerability of nicergoline
by: Amit Garg, et al.
Published: (2014-07-01)